{"id":482192,"date":"2020-05-04T07:48:01","date_gmt":"2020-05-04T07:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=482192"},"modified":"2020-05-04T07:48:01","modified_gmt":"2020-05-04T07:48:01","slug":"anemia-in-chronic-kidney-disease-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/anemia-in-chronic-kidney-disease-market-insights-epidemiology-and-market-forecast2030_482192.html","title":{"rendered":"Anemia in Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030"},"content":{"rendered":"
\"Anemia<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Anaemia in Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

(Albany, US) <\/span>DelveInsight launched a new report on Anemia in Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

Some of the key facts of the report<\/span>
1. The prevalence of anaemia increased with stage of Chronic Kidney Disease (CKD), from 8.4% at stage 1 to 53.4% in stage 5.<\/span>
2. 14.0% of the US adult population had Chronic Kidney Disease in 2007–2010.<\/span>
3. Anaemia was twice as prevalent in people with Chronic Kidney Disease (15.4%) as in the general population (7.6%).<\/span>
4. In patients with stage 3 Chronic Kidney Disease, 22.2% of patients with diabetes were anaemic, increasing to 52.4% in stage 4 CKD.<\/span><\/p>\n

Key benefits of the report<\/span>
1. Anaemia in Chronic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Anemia in Chronic Kidney Disease epidemiology and Anemia in Chronic Kidney Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Anaemia in Chronic Kidney Disease market report provides insights on the current and emerging therapies.<\/span>
3. Anaemia in Chronic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Anaemia in Chronic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Anemia in Chronic Kidney Disease market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

“At least 90% of patients who end up on dialysis will eventually develop anaemia of chronic disease.”<\/span><\/p>\n

Anaemia occurs in people with chronic kidney disease, which results in permanent, partial loss of kidney function. Anaemia might commence developing in the early stages of CKD when someone has 20 to 50 per cent of normal kidney function. Anaemia tends to exacerbate as CKD advances. Many people who have total loss of kidney function, or kidney failure, have anaemia. Currently, Anemia in Chronic Kidney Disease treatment paradigm involves the use of Iron therapies, Erythropoietin stimulating agent (ESA) therapies, Red Blood Transfusions, Vitamin B12 & Folic Acid Supplements and nutrition.<\/span><\/p>\n

ESAs and iron therapies are the most potent and commonly followed treatment procedures for anaemia associated with Chronic Kidney Disease. ESAs are used to stimulate erythropoiesis by either directly or indirectly acting on the erythropoietin receptor. There are two types of ESA therapies available in the United States, Europe and Canada named as Epogen (Epoetin Alfa) and Aranesp (Darbepoetin Alfa) for the treating anaemia associated due to chronic kidney disease.<\/span><\/p>\n

The development of recombinant EPO followed by erythropoiesis-stimulating agents (ESAs) revolutionized the management of anaemia in CKD. Although initially instituted to avoid transfusions, they were soon known to have various positive effects, including improved survival and quality of life, improved cardiac function and mortality associated with it, lower hospitalizations, and lower costs. Recombinant human erythropoietin and darbepoetin alfa are the two ESAs generally used in the management of anaemia in CKD. They are relatively similar in efficacy and side effect profile, except for the longer half-life of darbepoetin alfa, thus allowing for less frequent dosing.<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact Anemia in Chronic Kidney Disease treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span><\/p>\n

1. Evrenzo: Astellas Pharma\/ FibroGen<\/span><\/p>\n

And many others<\/span><\/p>\n

The key players in Anemia in Chronic Kidney Disease market are:<\/span>
1. Vifor Pharma Inc<\/span>
And many others<\/span><\/p>\n

Table of contents<\/span>
1. Report Introduction<\/span>
2. Anaemia in Chronic Kidney Disease Market Overview at a Glance<\/span>
3. Anaemia in Chronic Kidney Disease Disease Background and Overview<\/span>
4. Anaemia in Chronic Kidney Disease Epidemiology and Patient Population<\/span>
5. Anaemia in Chronic Kidney Disease Epidemiology by Countries (2017-2030)<\/span>
5.1. United States- Epidemiology (2017-2030)<\/span>
5.2. EU-5 – Epidemiology (2017-2030)<\/span>
5.3. Germany-Epidemiology (2017-2030)<\/span>
5.4. France-Epidemiology (2017-2030)<\/span>
5.5. Italy-Epidemiology (2017-2030)<\/span>
5.6. Spain-Epidemiology (2017-2030)<\/span>
5.7. United Kingdom-Epidemiology (2017-2030)<\/span>
6. Japan-Epidemiology (2017-2030)<\/span>
7. Anaemia in Chronic Kidney Disease Treatments and Medical Practices<\/span>
8. Anaemia in Chronic Kidney Disease Marketed therapies<\/span>
8.1. Mircera: Vifor Pharma Inc<\/span>
9. Anaemia in Chronic Kidney Disease Emerging Therapies<\/span>
10. Key Cross Competition<\/span>
10.1. Evrenzo: Astellas Pharma\/ FibroGen<\/span>
11. Anaemia in Chronic Kidney Disease Market Size<\/span>
12. 7MM Anemia in Chronic Kidney Disease: Country-Wise Market Analysis<\/span>
13. United States Market Size<\/span>
14. EU5 Market Size<\/span>
14.1. Germany Market Size<\/span>
14.2. France Market Size<\/span>
14.3. United Kingdom Market Size<\/span>
14.4. Spain Market Size<\/span>
14.5. Italy Market Size<\/span>
15. Japan Market Size<\/span>
16. Anaemia in Chronic Kidney Disease Report Methodology<\/span>
17. DelveInsight Capabilities<\/span>
18. Disclaimer<\/span>
19. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight’s “Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-482192","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=482192"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482192\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=482192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=482192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=482192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}